Table 2.
Medical treatment of 42 dogs with advanced myxomatous mitral valve disease.
| Medical Treatment | A History of Syncope, n (%) | No History of Syncope, n (%) |
|---|---|---|
| F | 3 (15.0) | 0 (0) |
| Pimo | 0 (0) | 1 (4.5)a |
| F + ACE‐I | 4 (20.0) | 3 (13.6) |
| F + Pimo | 1 (5.0) | 2 (9.0) |
| F + Dig | 1 (5.0) | 0 (0) |
| F + ACE‐I + ß‐blocker | 2 (10.0) | 0 (0) |
| F + ACE‐I + Pimo | 7 (35.0) | 7 (31.8) |
| F + ACE‐I + S | 0 (0) | 1 (4.5) |
| F + Pimo + Dig | 0 (0) | 1 (4.5) |
| F + Pimo + S | 0 (0) | 1 (4.5) |
| F + ACE‐I + Pimo + S | 1 (5.0) | 2 (13.6) |
| F + ACE‐I + Pimo + S + Dig | 0 (0) | 4 (18.2) |
| F + ACE‐I + Pimo + S + Dig + β‐blocker | 1 (5.0) | 0 (0) |
F, furosemide; ACE‐I, angiotensin‐converting enzyme inhibitor; Pimo, pimobendan; S, spironolactone; Dig, digoxin
a
This dog was started on and responded to furosemide treatment shortly after the examinations performed for this study.